Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Aandeel Pharming Group NL0010391025

Laatste koers (eur) Verschil Volume
0,800   -0,010   (-1,23%) Dagrange 0,798 - 0,811 5.639.674   Gem. (3M) 5,7M

Donderdag 17 juli - De Uitslag --> GOEDGEKEURD!

364 Posts
Pagina: 1 2 3 4 5 6 ... 19 »» | Laatste | Omlaag ↓
  1. [verwijderd] 17 juli 2014 07:02
    RUCONEST® (C1 ESTERASE INHIBITOR [RECOMBINANT]) 50 IU/kg IS THE FIRST AND ONLY RECOMBINANT TREATMENT OPTION FOR ADULT AND ADOLESCENT PATIENTS SUFFERING FROM HEREDITARY ANGIOEDEMA.

    LEIDEN, THE NETHERLANDS, RALEIGH (NC), July 17, 2014 - Pharming Group NV ( EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), today announced that the Food and Drug Administration has approved RUCONEST® (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Because of the limited number of patients with laryngeal attacks, effectiveness was not established in HAE patients with laryngeal attacks.

    Chekc. www.pharming.com
364 Posts
Pagina: 1 2 3 4 5 6 ... 19 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.